Glimison-M 2 Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 2mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, functions by stimulating pancreatic beta cells to increase insulin secretion, thereby lowering blood glucose levels. Metformin, a biguanide, primarily reduces hepatic glucose production and improves peripheral insulin sensitivity, contributing to enhanced glycemic control. This dual-action formulation offers complementary mechanisms to effectively manage hyperglycemia in patients inadequately controlled by diet and exercise alone. Glimison-M 2 Tablet PR is typically prescribed as part of a comprehensive diabetes management plan including lifestyle modifications such as diet and physical activity. It is important to monitor blood glucose levels regularly to adjust dosage and prevent hypoglycemia, a potential adverse effect associated with sulfonylureas. Metformin’s common side effects include gastrointestinal disturbances, which often subside with continued use. Contraindications include renal impairment, hepatic dysfunction, and conditions predisposing to hypoxia. Caution is advised in patients with cardiovascular disease or during radiologic studies involving iodinated contrast agents. Overall, Glimison-M 2 Tablet PR provides an effective therapeutic option for improving glycemic control in type 2 diabetes, enhancing patient outcomes when used under medical supervision.